MaxCyte raises full — year 2026 revenue guidance to about $34 million
MaxCyte raised full-year 2026 revenue guidance to about $34 million from $30 million-$32 million. Core business revenue outlook increased to about $28 million from $25 million-$27 million. SPL Program-related revenue forecast lifted to about $6 million from about $5 million, including about $4 million milestones, $2 mi